Pfizer’s Abrysvo is now approved for preventing illness caused by respiratory syncytial virus, or RSV, in adults 60 and older. The regulatory decision comes weeks after GSK won approval for its RSV vaccine, Arexvy.
Pfizer’s RSV Vaccine Wins FDA Approval on Heels of Regulatory Nod for GSK
